+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
From
From
Monoclonal antibodies - Competitive landscape, 2023 - Product Thumbnail Image

Monoclonal antibodies - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Thumbnail Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • October 2022
  • 300 Pages
  • Global
From
TIGIT Inhibitors - Competitive Landscape, 2022 - Product Thumbnail Image

TIGIT Inhibitors - Competitive Landscape, 2022

  • Report
  • October 2022
  • 100 Pages
  • Global
From
Antibody Drug Conjugates Market Report and Forecast 2024-2032 - Product Thumbnail Image

Antibody Drug Conjugates Market Report and Forecast 2024-2032

  • Report
  • September 2023
  • 140 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more